

SCREENING OF HYPERTENSIVE PATIENTS FOR HYPERLIPIDAEMIAS

Mumtaz Ali Shaikh and Rafi Ahmed Ghori

ABSTRACT

OBJECTIVES: This study was carried to screen out randomly hypertensive patients between 20 to 60 years of age; and to emphasize the presence of high lipids levels in hypertensive patients in our setup.

DESIGN: A Cross sectional study

PLACE AND DURATION: This study was conducted in the out door patients department of Liaquat University Hospital Hyderabad in the month of March 2003.

PATIENTS AND METHODS: Thirty hypertensive patients were screened randomly for hypercholesterolemia after obtaining their baseline information. Their ages were 20 to 60 years.

RESULTS: About forty seven percent of hypertensive patients, out of thirty patients were found to have plasma cholesterol level above 200 mg/dl and about fifty three percent of the patients with hypertension had plasma cholesterol level below 200 mg/dl.

CONCLUSION: Our findings show that hypertensive patients in our setup have significantly high abnormal lipid levels. So, while managing such patients our physicians should be careful in this regard.

KEY WORDS: *Hypertension. Hypercholesterolaemia.*

INTRODUCTION

Hyperlipidaemias cause hypertension indirectly by accelerating atherosclerosis. Both hypertension and hypercholesterolaemia are strong individual risk factors for ischaemic heart disease. But when combined can increase the risk for ischaemic heart disease drastically. People with combination of risk factors such as hypertension, hyperlipidaemias, smoking and diabetes have the greatest risk of developing coronary heart disease.

Hypercholesterolaemia is associated with increased incidence of cardiac events and characterized by impaired coronary vascular function, possibly mediated partly through increased pro-oxidative conditions in plasma and tissue. It has been studied that experimental hypercholesterolaemia is associated with blunted myocardial perfusion and increased vascular permeability responses in vivo to increased cardiac demand, which may be partly mediated by a shift in oxidative status^{1,2}. The incidence of coronary artery disease rises as blood pressure rises and the excess risk is related to both systolic and diastolic blood pressure. It has been observed that myocardial infarction patients displayed higher WBC count, higher fibrinogen, lower HDL cholesterol, lower apoA1 and higher lipoprotein (a) than patients who presented an uneventful clinical course that is stable angina without myocardial infarction³.

Patients with familial hyperlipidaemias have a high incidence of premature coronary artery disease and many epidemiological studies have demonstrated a positive correlation between mean population plasma cholesterol and morbidity and death from coronary disease. The excess risk is closely related to plasma concentration of low-density lipoprotein (LDL) cholesterol and is inversely related to high-density lipoprotein (HDL) cholesterol concentration. There are several potential mechanisms by which HDLs protect against the development of vascular disease. Different functions of HDLs complement their activity in arterial cholesterol removal by providing an excellent rationale for favorably influencing pathological processes underlying a variety of clinical conditions, such as accelerated atherosclerosis, acute coronary syndromes and restenosis after coronary angioplasty, through a chronic or acute elevation of plasma HDL concentration⁴. Large-scale randomized clinical trials have shown that lowering high cholesterol concentrations mainly by drugs reduces the risk of cardiac events. It is an observation that hyperlipidaemias are under treated. Only 1 patient out of 6 in the highest-risk class coronary artery disease patients who received lipid lowering drug treatment accomplished the LDL-Cholesterol goal of 100 mg/dl defined by the third report of the U. S. National Cholesterol Education Program (NCEP)⁵. Therefore, while managing the patients with

hypertension it is necessary to know which hypertensive patients have abnormal lipid levels? Though low density lipoprotein and ratio between low density lipoprotein and total cholesterol are more specific to define the added risk. But cholesterol level will help us to screen high risk patients. The cholesterol level below 250mg/dl is acceptable for normal persons. But patients having other risk factors the cholesterol level should be below 180mg/dl. In the large scale multiple risk factor intervention trial hypertensive men showed an increased risk for coronary artery disease with every increment in serum cholesterol from levels of 182 mg/dl⁶. Therefore, we conducted this study to see the hyperlipidemias in hypertensive patients through screening in our setup.

PATIENTS AND METHODS

This cross sectional study was carried out in the out door patients department (OPD) of Liaquat University Hospital Hyderabad in the month of March 2003. Thirty hypertensive patients were screened randomly for hypercholesterolaemia. Their ages were between 20 to 60 years. The complete history and physical examination was recorded from each individual. Blood pressure was measured by mercury sphygmomanometer from right arm kept at heart level after five minutes rest. Appearance of korat-koff's sound was taken as systolic and disappearance as diastolic blood pressure. Three readings were taken and an average of last two was recorded as the blood pressure of patient.

Blood cholesterol and blood sugar was determined by dry chemistry method utilizing a Boehringer mainheim Accutrend G. C. Blood was obtained from finger prick using mechanical gun. Patients were called in a hypertensive clinic they were not fasting and screened randomly without considering their drug regime or etc. Their electrocardiograph was also taken. An informed consent was obtained from all the patients included in this study.

RESULTS

In this study, thirty hypertensive patients were screened for plasma cholesterol level. Fourteen patients were male and sixteen were female. Out of these patients, two groups were made according to age. Group A, 20 years to 40 years of age and Group B, 41 years to 60 years of age. Nine (30%) hypertensive patients were in age group A, and twenty one (70%) hypertensive patients were in age group B. (Table I). Blood pressure readings of patients varied from 200---150/120---100 mmHg. Of these thirty hypertensive patients, fourteen (46. 6%) patients had plasma cholesterol level above 200mg/dl and of these hypercholesterolaemic patients, five (35.8%) were in

age group A and nine (64. 3%) in age group B. Among these fourteen patients male and female distribution was equal. (Table II)

Furthermore, seven (50%) of those hypercholesterolemic patients had ischaemic heart disease as evident on history and ECG changes. And other seven (50%) patients had diabetes mellitus as evident on history and blood sugar levels.

Table I showing age distribution of cases(n=30)

Age Group	No. of Cases
20 to 40 Years(Group A)	9(30%)
41 to 60 Years(Group B)	21(70%)

Table II showing hypercholesterolemia in cases (n=30)

Plasma Cholesterol >200mg/dl	Plasma Cholesterol <200mg/dl
In Group A: 5 Patients	In Group A: 4 Patients
In Group B: 9 Patients	In Group B: 12 Patients
Total: 14 Patients (46.6%)	Total: 16 Patients (53.4%)

DISCUSSION

Coronary artery disease remains the leading cause of death in developed countries, and advancing age increases the risk for this disease. Elevated serum concentration of total cholesterol and low density lipoprotein (LDL) cholesterol and low serum concentration of high density lipoprotein (HDL) cholesterol have been recognized as independent risk factors for coronary artery disease⁷. ApoA-I is the primary protein component of HDL and is thought to play an important role in mediating several of the atheroprotective effects of HDL. An inverse and independent association between plasma levels of apolipoprotein (apo) A-I and coronary heart disease in humans is well established The studies demonstrate that despite normal levels of HDL-C, apoA-I deficiency is associated with a significant loss of protection from the formation of atherosclerosis⁸. It has been found that the risk of a coronary event in men with the lipoprotein (a) • 0.2 g/liter was 2.7 times that of men with lower levels. This increase in risk was most prominent in men with high LDL cholesterol, low HDL-C, hypertension and / or high global cardiovascular risk⁹.

In United States, In patients with coronary artery disease, the cholesteryl ester transfer protein

7. Larosa JC, Hunniglake D, Bush D et al. The cholesterol fact: A summary of the evidence relating dietary fats, serum cholesterol and coronary artery disease. *Circulation* 1990.
8. Moore RE et al. Apolipoprotein A-I Deficiency results in Markedly Increased Atherosclerosis in Mice Lacking the LDL Receptor. *Arterioscler Thromb Vasc Biol.* 2003; 23:1914-20.
9. Arnold von Eckardstein. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. *Journal of American College of Cardiology.* 2001; 37(2): 434-439.
10. Stefan Blankenberg. Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. *Journal of American College of Cardiology.* 2003; 41(2): 1983-1989.
11. Dinco Susic et al. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. *Journal of American College of Cardiology.* 2003; 42 (6): 1091-1097.
12. Heart Protection Collaborative Study. Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes. *The Lancet.* 2003; 361 (9374): 2005-2016.
13. Anderson KM, Castell WP, Lerry DL. Cholesterol and Mortality. 30 years follow up from Framingham study. *JAMA.* 1987; 257: 2176.
14. Castel WP, Wilson PW and Levy D. Cardiovascular risk factors in elderly. *Am J Cardiol.* 1989; 63:12-19.
15. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes. *Am heart J.* 1986; III: 383.
16. Conner EB, Khaw KT. Family history of heart attacks as an independent mediator of death due to CVD. *Circulation.* 1984; 69:1065.
17. Kannel WB. Lipid, Diabetes and coronary heart disease. Insight from Framingham study. *Am Heart J.* 1985; 110-1100.
18. Gordon T, Kannel WB, Dawber TR. Lipoprotein, cardiovascular disease and death. The Framingham study. *Arch intern med.* 1990; 141: 1128.
19. Multiple risk factor intervention trial research group (MRFIT). *JAMA.* 1990; 63:1795.
20. Progot E, Murray JI. Smoking causes of death among US veterans. *Public Health R Ev.* 1980; 213:222.
21. Ken-ichiro Sasaki et al. Rescue of hypercholesterolemia-related impairment of angiogenesis by oral folate supplementation. *Journal of American College of Cardiology.* 2003; 42 (2): 16.
22. The greatest threat to women's health. Which disease kills the greatest number of women world wide? *The Lancet.* 2003: 9391:1165. 23&24 Hyperlipidaemias. *Postgraduate medicine.* 1994: 100(1)40-142.
23. Durrington PN et al. Indications for cholesterol-lowering medication: comparison of risk-assessment methods. *The Lancet.* 1999; 353 9149: 278-281.
24. Rosenberg L, Kauffman DW, Hullimnick SP. The risk of myocardial infarction after quitting smoking in man under 55 years of age. *N ENG J Med.* 1985; 313.
25. Samir R. Kapadia MD et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study. *Journal of the American College of Cardiology.* 2001: 38 (1): 206- 213.

.....
Correspondence:
Dr. Mumtaz Ali Shaikh
Assistant Professor
Department of Medicine
Isra University Hospital
Hala Road, Hyderabad, Sindh-Pakistan.

